Suggestions
Charles Baroud
Professor at Ecole Polytechnique, Unit head at Institut Pasteur
Charles Baroud is a distinguished professor at École Polytechnique, holding the title of "classe exceptionnelle," which indicates a high level of achievement and recognition in his field. He is also the head of a joint research group between Institut Pasteur and École Polytechnique focused on Physical Microfluidics and Bio-engineering.14
Baroud's academic background includes a Ph.D. from the Center for Nonlinear Dynamics, where he conducted an experimental study of turbulence in rotating flows.3 His career has been marked by significant contributions to the fields of microfluidics and bioengineering, where he has developed technologies for droplet generation and manipulation, subsequently transferring these technologies to industry through start-ups and licensing agreements.1
He has received several prestigious grants, including an ERC Starting Grant in 2011 and two ERC Proof of Concept Grants.1 Baroud's work spans multiple disciplines, integrating physical sciences, engineering, mathematical modeling, and biological applications.2 His current projects include collaborations aimed at improving cancer treatment through personalized approaches using microfluidic technologies.1
Highlights
Nanobiotech Montreux, first abstract deadline approaching at the end of the week.
Come join us in this beautiful place with a fantastic panel of speakers, covering the many aspects of microfluidics including bio-engineering, fundamental science, academia and industry. Speakers include Matthias Lutolf, Dino Di Carlo, Nicole Pamme, Rémi Dangla, David Issadore, and Simone Schurle-Finke.
Investigating the efficacy of cytotoxic T lymphocytes (CTLs) in eliminating tumor models is critical for gauging the success of cell therapies during their development or for quality control of #cartcells. However, the process of tumor destruction involves multiple steps including cell migration, antigen recognition, accumulation on the tumor, and actual killing. This complex chain of events makes it challenging to pinpoint weaknesses that may arise for different situations.
In our latest publication, we leverage our cutting-edge cancer-on-a-chip platform to understand how mutations in the adenomatous polyposis coli (APC) gene affect CTL behavior and their ability to destroy 3D tumor spheroids. We find that APC-mutated CTLs exhibit comparable migration around the tumor and accumulation on it. Once they reach the tumor however, they display reduced engagement with the cancer cells, which leads to reduced cytotoxicity of the APC mutant CTLs compared to control cells.
Our findings demonstrate the power of high-resolution spatio-temporal analysis to understand the interactions between immune cells and tumors. By employing this dynamic multiscale cytometry approach, we can dissect the different phases of CTL killing in order to identify variations between closely related cells.
Moreover, the cancer-on-a-chip platform provides a robust technology that can be generalized to various cell types. We expect that it will have a strong impact on cell and gene therapy developments, ultimately advancing the frontier of personalized cancer therapy.
These results are described in the recent paper in PNAS [https://lnkd.in/eUWrPBsN]. They come from a wonderful collaborative work with Valentin BONNET, Erik Maikranz, PhD, Andres Alcover, Vincenzo Di Bartolo, Nadia Vertti-Quintero, Marianne Madec, Marta Mastrogiovanni and Céline Cuche.
#ImmunoOncology #CancerResearch #PersonalizedMedicine #Microfluidics #celltherapy #cartcelltherapy
